CAC
ESLAW icon

Cowen and Company’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Cowen and Company’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,599
Closed -$2.29K – 113
2024
Q3 		$2.29K Buy
35,599
+9,800
+38% +$795 ﹤0.01% 573
2024
Q2 		$1.78K Sell
25,799
-2,798
-10% -$146 ﹤0.01% 580
2024
Q1 		$1.9K Hold
28,597
– – ﹤0.01% 633
2023
Q4 		$857 Hold
28,597
– – ﹤0.01% 568
2023
Q3 		$6.87K Buy
+28,597
New +$4.73K ﹤0.01% 498

Other funds holding ESLAW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Cowen and Company's ESLAW Position: Q4 2024 in Review

Cowen and Company sold out of Estrella Immunopharma Warrant (ESLAW) in Q4 2024, closing a stake of 35,599 shares — an estimated $2.29K sold.

Cowen and Company first reported a position in ESLAW in Q3 2023 and held it in 5 quarters. The position peaked at $6.87K in Q3 2023. 11 funds tracked by Wall St. Rank hold ESLAW as of Q4 2024.

  • Cowen and Company reported no remaining Estrella Immunopharma Warrant position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 35,599 Estrella Immunopharma Warrant shares in Q4 2024, an estimated $2.29K.
  • Cowen and Company first reported a position in Estrella Immunopharma Warrant in Q3 2023 and held it in 5 quarters.
  • Cowen and Company's Estrella Immunopharma Warrant position peaked at $6.87K in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.